ArticleScience translational medicine2013
Skinflammation and drug toxicity--a delicate balance.
Article in Science translational medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.JAMA oncology · 2016Trial
- Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy.Cancer discovery · 2021Article
- Proteomic and Phosphoproteomic Analysis Reveals that Neurokinin-1 Receptor (NK1R) Blockade with Aprepitant in Human Keratinocytes Activates a Distinct Subdomain of EGFR Signaling: Implications for the Anti-Pruritic Activity of NK1R Antagonists.Medicines (Basel, Switzerland) · 2019Article
- Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence.Scientific reports · 2017Article
- Differential Gene Expression in Erlotinib-Treated Fibroblasts.Nursing researchArticle
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Loss of epidermal growth factor receptor function in epidermal keratinocytes triggers a disfiguring acneiform rash through the coordinate activation of innate and adaptive immune defense mechanisms (Mascia et al. and Lichtenberger et al., this issue).
Indexed as
Identifiers
23966298What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.